Half of men and one-third of women will be diagnosed with cancer in their lifetime, according to the US National Cancer Institute. In 2020, liver cancer was the sixth most common cancer and third leading cause of cancer death in the world.
The current screening standard for people at increased risk of liver cancer doesn't decrease mortality from the disease.
That's why we're developing an early detection test for liver cancer, also called hepatocellular carcinoma (HCC), to detect liver cancer at its earliest, most treatable, stages.
Chronic hepatitis B and C are recognized as the major factors worldwide increasing the risk of HCC. Cirrhosis is also a risk factor, whether it's from alcohol consumption or not, because nonalcoholic cirrhosis is just as much of a risk for liver cancer (NCI).
We're working to develop serum biomarker testing for early detection of hepatocellular carcinoma, or liver cancer, as well as for NASH staging and diagnosis.
Our approach includes identifying metabolic profiles comprised of biomarkers specific to these diseases and providing analysis by nuclear magnetic resonance (NMR) spectroscopy.
Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.
Our FDA-cleared AXINON® System is the core technology platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases.
This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.
To date, more than 3 million tests have been performed globally using our technology.
